Design Net Interest Income from 2010 to 2026
| DSGN Stock | USD 10.27 0.32 3.22% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter 14.7 M | Current Value 13.3 M | Quarterly Volatility 957.4 K |
Check Design Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Design Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 719.7 K, Interest Expense of 5.7 M or Selling General Administrative of 13.3 M, as well as many indicators such as Price To Sales Ratio of 1.1 M, Dividend Yield of 0.0 or PTB Ratio of 1.36. Design financial statements analysis is a perfect complement when working with Design Therapeutics Valuation or Volatility modules.
Design | Net Interest Income | Build AI portfolio with Design Stock |
Evaluating Design Therapeutics's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Design Therapeutics's fundamental strength.
Latest Design Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Design Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Design Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Design Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Design Net Interest Income Regression Statistics
| Arithmetic Mean | 11,727,582 | |
| Geometric Mean | 11,694,547 | |
| Coefficient Of Variation | 8.16 | |
| Mean Deviation | 658,136 | |
| Median | 11,328,000 | |
| Standard Deviation | 957,428 | |
| Sample Variance | 916.7B | |
| Range | 3.4M | |
| R-Value | 0.62 | |
| Mean Square Error | 600.9B | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 117,703 | |
| Total Sum of Squares | 14.7T |
Design Net Interest Income History
About Design Therapeutics Financial Statements
Design Therapeutics investors utilize fundamental indicators, such as Net Interest Income, to predict how Design Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 14.7 M | 13.3 M |
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Design Stock
Moving against Design Stock
| 0.78 | GNLX | Genelux Common | PairCorr |
| 0.75 | EVGN | Evogene | PairCorr |
| 0.73 | EDIT | Editas Medicine | PairCorr |
| 0.7 | QSI | QuantumSi | PairCorr |
| 0.69 | LYRA | Lyra Therapeutics | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Design Therapeutics Correlation against competitors. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Will Biotechnology sector continue expanding? Could Design diversify its offerings? Factors like these will boost the valuation of Design Therapeutics. Projected growth potential of Design fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Design Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Design Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Design Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Design Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Design Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Design Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Design Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.